A Pharmaceutico-Analytical and Clinical study ofSaubhagyadi Gutika on Pain during menstruatio
- Conditions
- Health Condition 1: N944- Primary dysmenorrhea
- Registration Number
- CTRI/2021/03/032166
- Lead Sponsor
- State Ayurvedic College and Hospital Lucknow
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
1. Patients who are suffering from primary dysmenorrheal.
2. Patient comes with chief complaint of pain during menses along with associated
symptoms.
3. Patients within the age group 18-40 years.
4. Patients suffering for more than 3 consecutive cycles.
5. Patient with H/O using analgesics and other drug during menses.
1.Patients below 18 and above 40 years of age.
2. Patients suffering from secondary dysmenorrhea; having organic pathology of uterus
and adenexa. e.g.- Fibroid uterus, carcinoma of endometrium, venereal diseases ,PID,
adenomyosis, endometriosis etc.
3. Patients suffering from systemic diseases.
4. Patient using intra uterine contraceptive devices.
5. Those under any hormonal therapy.
6. Patients having Pain abdomen associated with excessive bleeding p/v.
7. Patients with H/O thyroid dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess the efficacy of Saubhagyadi Gutika <br/ ><br>2.To assess the efficacy of trial drug on subjective parameter severity of pain,duration of pain,site of pain, nature of painTimepoint: Final assessment will be done after completion of trial of four consecutive menstrual cycles.
- Secondary Outcome Measures
Name Time Method To assess the efficacy of trial drug on associated symptoms Praseka (Nausea),Chhardi (Vomiting),Vibandha (Constipation) ,Atisara (Diarrhea),Aruchi (Loss of <br/ ><br>appetite),Shrama (Fatigue),Shirashula (Headache),Vankshana Shula (tenesmus of the bladder), Kati Shula, <br/ ><br>and Janu Shula,Swedadikya (excessive sweating),Tamodarshana (Faints)Timepoint: Follow up- each menstrual cycle during trial.